Molnunat
Intended to target viral replication in COVID-19, designed to alleviate clinical symptoms and support recovery in patients with mild-to-moderate infection.
Strengths: 200mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Lagevrio
- Therapeutic class
Antiviral
- Pharmacological class
Nucleoside Analogue
- Contraindications
hypersensitivity to active ingredient
- Precautions and warnings
not for use as post-exposure prophylaxis; complete full course of treatment
- Minor side effects
diarrhoea; nausea
- Moderate side effects
dizziness
- Serious side effects
anaphylaxis — requires immediate medical attention
- Dosage forms
Capsule, hard
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Natco Pharma
- Onset Time
1–2 days
- Duration
5 days
- Storage instructions
Store below 30°C.
- Age restrictions
18 years and older with risk factors.
- Pregnancy and breastfeeding
Not recommended during pregnancy.
Patient summary
Intended to target viral replication in COVID-19, designed to alleviate clinical symptoms and support recovery in patients with mild-to-moderate infection.
Mechanism of action
Molnupiravir is a prodrug that acts as a nucleoside analogue. When metabolized, it incorporates into the viral RNA during replication, causing a high mutation rate in the SARS-CoV-2 genome, which effectively inhibits viral progression.
Molnunat
Intended to target viral replication in COVID-19, designed to alleviate clinical symptoms and support recovery in patients with mild-to-moderate infection.
Editorial Notes
- Active ingredient(s): Molnupiravir
- Listed indication(s): Covid-19
Available option
- 1 bottle - 200 mg994-200-mg-12537